The influence of morning versus evening administration on tamoxifen pharmacokinetics - Morning versus evening administration of tamoxifen

未提供0 个研究点目标入组 18 人开始时间: 2012年3月5日最近更新: 2012年7月10日

适应症

试验速览

暂无简介。

•-Histological or cytological confirmed diagnosis of breast cancer, for which treatment with tamoxifen is indicated (to be evaluated by the treating physician);
•-Use of tamoxifen for at least 4 weeks and willing to continue the treatment until the end of the study;
•-Age > 18 years;
•-WHO performance = 1;
•-Written informed consent;
•-Adequate renal and hepatic functions;
•-Adequate hematological blood counts;
•-No chemotherapy within the last 4 weeks before start;
•-No radiotherapy within the last 4 weeks before start.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 18
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•-Pregnant or lactating patients;
•-Serious illness or medical unstable condition requiring treatment, symptomatic CNS metastases or history of psychiatric disorder that would prohibit the understanding and giving of informed consent;
•-More than one dose of tamoxifen (20 or 40 mg) per day;
•-Non-compliance.

发起方

未提供